[artículo] 
inJournal of the American Academy of Child & Adolescent Psychiatry > Año 2025 - Vol. 64 - No. 7 (July) . - 755-756

Título :	Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise
Tipo de documento:	texto impreso
Fecha de publicación:	2026
Artículo en la página:	755-756
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Etiquetas:	Alucinógenos efectos adversos, Alucinógenos uso terapéutico, Equilibrio terapéutico, Seres humanos, Adolescentes.
Resumen:	We read with interest the Commentary by Jeffrey et al. encouraging clinical research using psychedelics for adolescents.1 Throughout their commentary, the authors operate under the general presupposition that psychedelics have demonstrated a favorable safety profile in adults, and that therefore teenagers approaching an adult level of neurodevelopment can likely be safely treated with appropriate safeguards. Although we concur that there is an urgent need for new psychopharmaceuticals for adolescents, we question this assumption of safety, given increasing evidence of risks associated with psychedelics in adult trials.2,3. (Copyright © 2024 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.)
En línea:	https://doi.org/10.1016/j.jaac.2024.12.001
Link:	./index.php?lvl=notice_display&id=31636

[artículo] Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise [texto impreso] . - 2026 . - 755-756.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of the American Academy of Child & Adolescent Psychiatry > Año 2025 - Vol. 64 - No. 7 (July) . - 755-756

Etiquetas:	Alucinógenos efectos adversos, Alucinógenos uso terapéutico, Equilibrio terapéutico, Seres humanos, Adolescentes.
Resumen:	We read with interest the Commentary by Jeffrey et al. encouraging clinical research using psychedelics for adolescents.1 Throughout their commentary, the authors operate under the general presupposition that psychedelics have demonstrated a favorable safety profile in adults, and that therefore teenagers approaching an adult level of neurodevelopment can likely be safely treated with appropriate safeguards. Although we concur that there is an urgent need for new psychopharmaceuticals for adolescents, we question this assumption of safety, given increasing evidence of risks associated with psychedelics in adult trials.2,3. (Copyright © 2024 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.)
En línea:	https://doi.org/10.1016/j.jaac.2024.12.001
Link:	./index.php?lvl=notice_display&id=31636